FIELD: medicine.
SUBSTANCE: invention refers to biotechnology and medicine. What is presented is a method for differentiation of mesenchymal stem cells of fibrotic lungs into fibroblastic cells, characterised by recovering the cells self-maintaining in vitro for 60 days and having mesenchymal stem cell phenotype (CD44+, CD73+, CD90+, CD106+, CD31-, CD34-, CD45-) from the right lobe of fibrotic lungs and producing the fibroblastic cells when adding fibroblast growth factor 2 mcg/ml to the mesenchymal stem cell culture.
EFFECT: method enables producing the donor cells from the patients suffering idiopathic fibrosis from fibrotic pulmonary tissues.
3 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRODUCING AND MAINTAINING MESENCHYMAL STEM CELLS FROM MAMMALIAN BONE MATERIAL | 2023 |
|
RU2821926C1 |
| HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | 2014 |
|
RU2679500C2 |
| HUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS | 2013 |
|
RU2668389C2 |
| METHOD OF ACCELERATED ACQUIRING OF MESENCHYMAL STEM CELLS (MSC) CULTURE OF MAMMALS, EXCEPT HUMAN, WITH LOW HETEROGENEITY AND HIGH VIABILITY | 2007 |
|
RU2331670C1 |
| METHOD FOR TREATING FROSTBITE USING MESENCHYMAL STEM CELLS ISOLATED FROM RED BONE MARROW | 2020 |
|
RU2748539C1 |
| METHOD FOR TREATMENT OF ALLERGIC RESPIRATORY TRACT DISEASE (AAD)/ASTHMA | 2018 |
|
RU2790031C2 |
| LINE OF MULTIPOTENT MESENCHYMAL STEM SELLS OF HUMAN SUBCUTANEOUS FATTY TISSUE (PANNICULUS ADIPOSUS HOMO SAPIENSE) FOR CELL AND TISSUE ENGINEERING | 2007 |
|
RU2354693C2 |
| MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS | 2015 |
|
RU2715866C2 |
| METHOD FOR PRODUCTION OF MESENCHYMAL STEM CELLS AND BIOTRANSPLANT USING THE SAME | 2006 |
|
RU2303631C1 |
| METHOD FOR EVALUATING AND MONITORING IN VITRO PURITY OF A CELL PREPARATION, USE OF A GROWTH FACTOR, A KIT | 2016 |
|
RU2738969C2 |
